Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
What the film says
This trial is for brain cancer in children and young adults, ages 3 to 25, that has progressed or not responded to treatment, including ependymoma, medulloblastoma and glioblastoma.
The idea: combine immune and chemotherapy drugs. Ibrutinib is added to indoximod with either cyclophosphamide and etoposide, or temozolomide, in cycles of at least 28 days. Patients need MRI confirmation of active disease.
This phase 1 study finds the best safe dose of ibrutinib, and plans 37 participants. At Augusta University in Georgia, Theodore Johnson leads it.
Public record; not medical advice.
Sources behind this film
Ages 3 to 25, progressive or refractory brain cancer incl. ependymoma, medulloblastoma, glioblastoma; Ibrutinib added to indoximod with cyclophosphamide and etoposide, or temozolomide; cycles of at least 28 days; Phase 1; best safe dose of ibrutinib; Augusta University, Georgia; Theodore Johnson (+2 more lines)
The drug
Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
For Regimen A, Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
The GCC2020 trial is a prospective open-label phase 1 trial to determine the best safe dose of the BTK-inhibitor ibrutinib to use in combination with previously studied chemo-immunotherapy regimens comprised of the investigational IDO-inhibitor indoximod plus oral palliative chemotherapy for participants, age 6 to 25 years, with relapsed or refractory primary brain cancer.
The study
Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells.
The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) with indoximod (IDO-inhibitor) during chemotherapy will synergistically enhance anti-tumor immune responses, leading to improvement in clinical response with manageable overlapping toxicity.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.